AACR

An interview with: Adetunji T. Toriola, MD, PhD, MPH, Professor of Surgery, Department of Surgery and Division of Public Health Sciences, Washington University School of Medicine and Siteman Cancer Ce

An interview with: Adam Thiesen, PhD Candidate, UConn Health, University of Connecticut and the Jackson Laboratory for Genomic Medicine, Farmington,  CT And with: Jayesh Desai MD, Medical Oncologist,

An interview with: Jiafu Ji MD PhD DrPH FRCS, Fellow of the Chinese Academy of Medical Science, Professor and Chief, Gastrointestinal Cancer Center, Peking University Cancer Hospital, Beijing Institut

An interview with: Ajay Goel PhD, Chair of the Molecular Diagnostics and Experimental Therapeutics Department, Beckman Research Institute, City of Hope, Los Angeles California.  SAN DIEGO—The prospect

An interview with: Sundar Jagannath MBBS, Professor of Medicine, Hematology and Medical Oncology, Director of the Center of Excellence for Multiple Myeloma, Icahn School of Medicine, Mount Sinai, New

An interview with: Olivier Lantz MD PhD, Head of the Clinical Immunology Laboratory, Institut Curie, Paris, France PARIS, France—A clinical trial using a personalized therapeutic vaccine, that

Audio Journal of Oncology Patients with Desmoplastic Melanoma Were Exceptional Responders to Single Agent Pembrolizumab LOS ANGELES, CA—Single agent immunotherapy with the anti-programmed death-1 (PD-

WASHINGTON DC—Doctors taking the unusual step of combining two experimental drugs to treat cancers in patients who have mutated BRCA — the gene conferring susceptibility to breast, ovarian and some ot

WASHINGTON DC—Laboratory evidence that giving patients intermittent rather than continuous treatment with cancer drugs could help them overcome drug resistance in cancers such as melanoma was presente

WASHINGTON DC—Gene expression and molecular pathways in head and neck cancer have been identified with reference to The Cancer Genome Atlas in research presented at the American Association for Cancer

WASHINGTON DC—Patients with metastatic breast cancer who are HER-2 positive could potentially be treated with the anti-HER-2 conjugated drug, trastuzumab-emtansine (T-DM1), alone — without needing to

WASHINGTON DC—A new type of immunotherapy has helped patients with advanced ovarian cancer who had no other therapeutic options. In a study reported to the 2013 conference of the American Association

ORLANDO—A rare inherited form of skin cancer — basal cell nevus syndrome — has been controlled by an inhibitor of the “hedgehog” molecular pathway in a study reported to the American Assoc

ORLANDO—Evidence that cancer could be controlled more effectively by blocking two molecular pathways simultaneously was reported at the American Association for Cancer Research annual meeting in Orlan

Pierre Laurent-Puig Bill Hait REFERENCE: ABSTRACT: 5671, American Association for Cancer Research, April 14-18, 2007, Los Angeles PIERRE LAURENT-PUIG, Hôpital Européen Georges Pompidou, Paris COMMEN

Paul Fisher REFERENCE: Meet the Professor Session, AACR 2007, Los Angeles PAUL FISHER, Columbia University, New York Patients with cancer could soon be treated with adenoviruses capable of infecting b

Jorma Paavonen REFERENCE: Lancet 369:2161-2170, 2007 JORMA PAAVONEN, University of Helsinki High efficacy of the bivalent vaccine for human papillomavirus is reported in the Lancet by an international

Alberto Sobrero Cetuximab With Irinotecan: Phase III Study Shows Benefit in Patients with Oxaliplatin-Refractory Colorectal Cancer REFERENCE: ABSTRACT LB-2; AACR 2007, Los Angeles, Plenary Session ALB

Fritz Schröder Opportunistic Prostate Screening May Not Save Lives! REFERENCE: AACR 2007, Los Angeles FRITZ SCHRÖDER, Erasmus University, Rotterdam Though elective screening appears to have reduced